|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300075959 |
|
最近更新日期: Date of Last Refreshed on: |
2023-09-20 14:59:33 |
|
注册时间: Date of Registration: |
2023-09-20 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
亚临床社交焦虑认知行为干预脑影像研究 |
|
Public title: |
Neuroimaging study of cognitive-behavioral intervention in subclinical social anxiety |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
亚临床社交焦虑认知行为干预脑机制研究 |
|
Scientific title: |
Neuroimaging study of cognitive-behavioral intervention in subclinical social anxiety |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
黄芳芳 |
研究负责人: |
黄芳芳 |
|
Applicant: |
Fangfang Huang |
Study leader: |
Fangfang Huang |
|
申请注册联系人电话: Applicant telephone: |
+86 152 3620 8605 |
研究负责人电话: Study leader's telephone: |
+86 152 3620 8605 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
149428274@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
149428274@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
河南省洛阳市洛龙区开元大道263号 |
研究负责人通讯地址: |
河南省洛阳市洛龙区开元大道263号 |
|
Applicant address: |
No. 263, Kaiyuan Avenue, Luoyang, Henan |
Study leader's address: |
No. 263, Kaiyuan Avenue, Luoyang, Henan |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
河南科技大学 |
||
|
Applicant's institution: |
Henan University of Science and Technology |
||
|
研究负责人所在单位: |
河南科技大学 |
||
|
Affiliation of the Leader: |
Henan University of Science and Technology |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023-03-K0044 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
河南科技大学第一附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Institutional Review Board of First Affiliated Hospital of Henan University of Science and Technology |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-07-21 00:00:00 |
||
|
伦理委员会联系人: |
朱珊 |
||
|
Contact Name of the ethic committee: |
Shan Zhu |
||
|
伦理委员会联系地址: |
河南省洛阳市涧西区景华路24号 |
||
|
Contact Address of the ethic committee: |
No. 24, Jinghua Road, Luoyang, Henan |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 379 6492 2216 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
河南科技大学第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The first affiliated Hospital, Henan University of Science and Technology |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
河南省洛阳市洛龙区开元大道263号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 263, Kaiyuan Avenue, Luoyang, Henan |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
河南省科技攻关项目 (212102310583), 河南省自然科学基金项目 (232300420267), 河南省高等学校重点科研项目 (23A330005) |
||||||||||||||||||||||
|
Source(s) of funding: |
Key Specialized Research and Development Breakthrough in Henan Province (212102310583), Natural Science Foundation of Henan Province (232300420267), Key Scientific Research Project of Colleges and Universities in Henan Province (23A330005) |
||||||||||||||||||||||
|
Target disease: |
Subclinical Social Anxiety |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
1. 通过比较亚临床社交焦虑被试和健康对照脑核磁共振影像数据,研究亚临床社交焦虑脑机制。 2. 通过比较认知行为干预前后亚临床社交焦虑被试脑核磁共振影像改变,研究认知行为干预的脑机制。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To study the brain mechanisms of subclinical social anxiety by comparing the MRI data of subjects with subclinical social anxiety and healthy controls. 2. To study the brain mechanisms of cognitive-behavioral intervention by comparing the MRI data of subjects with subclinical social anxiety before and after intervention. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
本研究的研究对象为亚临床社交焦虑者和健康对照,样本来源于河南科技大学大学生群体。本研究采用中文版国际神经精神科简式访谈问卷7.0(MINI7.0)对亚临床社交焦虑进行操作定义。 (1)亚临床社交焦虑组纳入标准:1)评估为亚临床社交焦虑的个体,即满足MINI7.0标准F1(对社交情境存在显著的恐惧),但有一个或多个其他标准(F2至F6)缺失;2)确认社交问题是焦虑情绪的主要来源;3)24-项自评Liebowitz社交焦虑量表(LSAS)评分≥ 40;4)抑郁自评量表(SDS)评分<40;5)右利手;6)年龄>18周岁。 (2)健康对照组纳入标准:1)自我报告无社交焦虑或其它情绪问题;2)24-项自评Liebowitz社交焦虑量表(LSAS)评分<20; 3)抑郁自评量表(SDS)评分<40;4)焦虑自评量表(SAS)评分<40;5)右利手;6)年龄>18周岁。 |
||||||||||||||||||||||
|
Inclusion criteria |
The subjects of this study were individuals with subclinical social anxiety and healthy controls, and the samples were from college students at Henan University of Science and Technology. Participants were included into the subclinical social anxiety group if they met the following criteria: 1) meeting MINI social anxiety disorder criterion F1 (presence of strong fears regarding social and performance situations), but having one or more other criterion (F2 to F6) missing; 2) confirming that social problems were the major source of their anxiety emotion; 3) 24-item self-administered Liebowitz Social Anxiety Scale total score ≥ 40; 4) Zung Self-Rating Depression Scale score < 40; 5) right-handed; 6) age > 18. Participants were included into the healthy control group if they met the following criteria: 1) Self-stating not plagued by social anxiety or other emotion problems; 2) Liebowitz Social Anxiety Scale total score < 20; 3) Zung Self-Rating Depression Scale score < 40; 4) Zung Self-Rating Anxiety Scale score < 40; 5) right-handed; 6) age > 18. |
||||||||||||||||||||||
|
排除标准: |
(1)亚临床社交焦虑组排除标准为:1)具有脑器质性疾病、重大躯体疾病、传染病的患者;2)目前或既往患有符合DSM-5诊断精神障碍和人格障碍;3)单纯演讲焦虑;4)具有药物依赖及精神活性物质使用证据;5)正在或曾经使用过抗精神疾病药物或其他可能影响脑功能的药物,正在或曾经接受过心理咨询或治疗;6)具有核磁扫描禁忌症. (2)健康对照组排除标准:1)具有脑器质性疾病、重大躯体疾病、传染病的患者;2)目前或既往患有符合DSM-5诊断精神障碍和人格障碍;3)具有药物依赖及精神活性物质使用证据;4)正在或曾经使用过抗精神疾病药物或其他可能影响脑功能的药物,正在或曾经接受过心理咨询或治疗;5)具有核磁扫描禁忌症. |
||||||||||||||||||||||
|
Exclusion criteria: |
Exclusion criteria for subclinical social anxiety disorder group: 1) patients with organic brain diseases, major physical diseases, infectious diseases; 2) currently or previously suffering from a DSM-5 diagnosed mental disorder and personality disorder; 3) subjects’ fear was limited to public speaking or performance; 4) evidence of drug dependence and psychoactive substance use; 5) are using or have used antipsychotic drugs or other drugs that may affect brain function, are receiving or have received psychological counseling or treatment; 6) having contraindications to nuclear magnetic scanning. Exclusion criteria for healthy control group: 1) patients with organic brain diseases, major physical diseases, infectious diseases; 2) currently or previously suffering from a DSM-5 diagnosed mental disorder and personality disorder; 3) evidence of drug dependence and psychoactive substance use; 4) are using or have used antipsychotic drugs or other drugs that may affect brain function, are receiving or have received psychological counseling or treatment; 5) having contraindications to nuclear magnetic scanning. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-07-01 00:00:00至 To 2025-07-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-09-25 00:00:00 至 To 2024-01-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
None |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集:采用病历记录表收集基本信息、24-项自评Liebowitz社交焦虑量表评估社交焦虑水平,由具有精神科医师作为评估员完成;使用核磁共振扫描(MRI)收集脑影像数据,在河南科技大学第一附属医院影像中心由影像技师完成。数据管理:基本信息、量表值使用EXCEL表格管理,采用双录入,并经过核查;脑影像数据拷贝至光盘进行存放和管理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection: Case Record Form is used to collect basic information and 24-item self-rated Liebowitz social anxiety Scale is used to assess social anxiety level, which is completed by a psychiatrist as evaluator; Brain image data were collected using magnetic resonance scanning (MRI), which is conducted by imaging technicians at the Imaging Center of the First Affiliated Hospital of Henan University of Science and Technology. Data management: Basic information and scale scores are managed in EXCEL with double input and verified; Brain image data are copied to CD for storage and management. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |